Dr Suner

Ivan J. Suñer, MD, MBA

Education:

  1. Antilles High School, 1984
    Ft. Buchanan, PR, Valedictorian
  2. Harvard University,1988, Bachelor of Arts, Magna cum laude
    Cambridge, MA
  3. Yale University,1992, M.D.
    New Haven, CT
  4. University of South Florida, 2005,
    Masters in Business Administration (Health Administration and Finance)
    Tampa, FL

Professional Training:

  1. Norwalk Hospital/Yale University School of Medicine
    Internship-Internal Medicine 1992-1993
  2. University of Miami-Bascom Palmer Eye Institute
    Residency in Ophthalmology 1993-1996
  3. University of Miami-Bascom Palmer Eye Institute
    Fellowship-Vitreoretinal Diseases and Surgery 2000-2002

Employment:

  1. U.S. Air Force-Scott Air Force Base, IL
    Chief of Ophthalmology 1996-2000
  2. Washington University-St. Louis
    Assistant Professor of Ophthalmology 1997-2000
  3. University of Miami-Bascom Palmer Eye Institute
    Assistant Professor of Ophthalmology 2000-2005
  4. Miami Veterans Affairs Medical Center
    Staff Ophthalmologist 2000-2002
  5. Miami Veterans Affairs Medical Center
    Chief of Ophthalmology Section 2002-2005
    Associate Chief of Surgery Service 2003-2005
  6. Duke Eye Center-Duke University Medical Center
    Associate Professor of Ophthalmology 2005-2008
  7. Durham Veterans Affairs Medical Center
    Chief of Ophthalmology Section 2005-2008
    Associate Chief of Surgery Service
  8. Retina Associates of Florida, P.A.
    Private Practice – Limited to Diseases and Surgery
    of Retina and Macula 2009-present
    Associates: W. Sanderson Grizzard, M.D., Mark E. Hammer, M.D.
  9. Univ of South Florida Department of Ophthalmology
    Clinical Associate Professor of Ophthalmology 2010-present
  10. Memorial Hospital of Tampa
    2013 – 2014
    Chief of Surgery
  11. Memorial Hospital of Tampa
    2015 – 2016
    Associate Chief of Staff

Medical Licensure:

  1. National Board of Medical Examiners, 1993
  2. Florida #ME-0064994, issued 7/1993
  3. North Carolina #2005-01163, issued 9/2005
  4. Drug Enforcement Agency – BS6686349

Professional Certification:

  1. Diplomate, National Board of Medical Examiners, 1993, Candidate #415499
  2. Diplomate American Board of Ophthalmology, 1998; recertification valid to 2018

Scholarly Societies:

  1. American Academy of Ophthalmology
  2. The Retina Society
  3. The Macula Society
  4. American Society of Retina Specialists
  5. European Vitreoretinal Society
  6. American Board of Ophthalmology, Oral Boards Examiner
  7. Club Vit
  8. Aspen Retinal Detachment Society

Papers and Publications:

A) Refereed Journals:

  1. Ramírez-Rivera J, Suñer-Doran IJ. False unilateral hyperlucent lung: a trapped lung with persistent pneumothorax. Bol Asoc Med P Rico 1987;79:247-250.
  2. Rakic P, Lidow M, Meinecke D, Suñer I. Intrinsic and extrinsic determinants of cerebral cortical areas. Cold Spring Harbor Symposium 1990;55:83.
  3. Rakic P, Suñer I, Williams RW. A novel cytoarchitectonic area induced experimentally within the primate visual cortex. Proc Natl Acad Sci USA 1991;88:2083-2087.
  4. Suñer I, Rakic P. Numerical relationship between neurons in the lateral geniculate nucleus and primary visual cortex in macaque monkeys. Vis Neurosci 1996;13:585-590.
  5. Greenfield DS, Suñer IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW. Endophthalmitis following filtering surgery with mitomycin. Arch Ophthalmol 1996;114:943-949.
  6. Greenfield DS, Miller MP, Suñer IJ, Palmberg PF. Needle elevation of the scleral flap for failing filtration blebs after trabeculectomy with mitomycin C. Am J Ophthalmol 1996;122:195-204.
  7. Suñer IJ, Greenfield DS, Miller MP, Palmberg PF. Hypotony maculopathy following filtration surgery with mitomycin C. Ophthalmology 1997;104:207-215.
  8. Suñer IJ, González C. Congenital absence of meibomian glands in the Setleis forceps marks syndrome. J Ped Ophthalmol & Strabismus 1997;34:378-380.
  9. Suñer IJ, Meldrum ML, Johnson TE, Tse DT. Necrotizing fasciitis after cosmetic blepharoplasty. Am J Ophthalmol 1999;128:367-368.
  10. Espinosa-Heidmann DG, Suñer IJ, Hernandez EP, Frazier WD, Csaky KG, Cousins SW. Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthal Vis Sci 2002;43:1567-1573.
  11. Espinosa-Heidmann DG, Suñer IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthal Vis Sci 2003;44(8):3586-3592.
  12. Suñer IJ, Espinosa-Heidmann DG, Marin-Castaño ME, Hernandez EP, Pereira-Simon S, Cousins SW. Nicotine increases size and severity of choroidal neovascularization, Invest Ophthal Vis Sci 2004;45(1):311-317.
  13. Miller DM, Espinosa-Heidmann DG, Legra J, Dubovy SR, Suñer IJ, Sedmak DD, Dix RD, Cousins SW. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration, Am J Ophthalmol 2004;138:323-328.
  14. Espinosa-Heidmann DG, Suñer IJ, Catanuto P, Hernandez EP, Marin-Castaño ME, Cousins SW. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of Dry AMD. Invest Ophthal Vis Sci 2006;27:729-737.
  15. Matchar DB, Suñer IJ, Samsa GP, McCrory DC, Cline K, Lee PP. Measuring Quality of Life for Patients with Age-Related Macular Degeneration. Agency for Healthcare Research and Quality (US) (Internet)
  16. Bearelly S, Mruthyunjaya P, Tzeng JP, Suñer IJ, Shea AM, Lee JT, Kowalski JW, Curtis LH, Schulman KA, Lee PP. Identification of patients with diabetic macular edema from claims data: a validation study. Arch Ophthalmol 2008;126:986-989.
  17. Friberg TR, Gupta A, Yu J, Huang L, Suñer I, Puliafito CA, Schwartz SD. Ultrawide angle fluorescein angiographic imaging: a comparison to conventional digital acquisition systems. Ophthalmic Surg Lasers Imaging 2008;39:304-311.
  18. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: Validation studies from two phase 3 clinical trials. Invest Ophthal Vis Sci 2009;50:3629-3635.
  19. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-1114.
  20. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
  21. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Am J Ophthalmol. 2009;148:725-732.
  22. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, Ianchulev T; MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117:747-756.
  23. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
  24. Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, Danese MD, Yu E, Tran I, Colman S. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129:709-17.
  25. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98.
  26. Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: Results from the BRAVO and CRUISE Trials. Ophthalmology. 2012;119:2108-18.
  27. Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan CM, Ward J, Ianchulev T, Fine J. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology. 2013;120:160-8.
  28. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group, 12-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology. 2013: 120;1046-1056.
  29. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J, Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013:120;1860-70.
  30. Suñer IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol. 2013:131;851-6.
  31. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials CATT Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmology. 2014;132:521-7.
  32. Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol. 2014;158:128-35.
  33. Suñer IJ, Margolis J, Ruiz K, Tran I, Lee P. Direct medical costs and resource use for treating central and branch retinal vein occlusion in commercially insured working-age and medicare populations. Retina. 2014;34:2250-8.
  34. Bressler NM, Varma R, Suñer IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A, RIDE and RISE Research Groups. Vision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema: Results from RIDE and RISE. Ophthalmology. 2014;121:2461-72.
  35. Altaweel MM, Martin DE, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; CATT Research Group. Outcomes of Eyes with Lesions of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015;122:391-8.
  36. Suñer IJ, Peden MC, Hammer ME, Grizzard WS,Traynom J, Cousins SW. RaScaL: A Pilot Study to Assess the Efficacy, Durability, and Safety of a Single Intervention with Ranibizumab + Peripheral Laser for Diabetic Macular Edema Associated with Peripheral Nonperfusion on Ultrawide-field Angiography. Ophthalmologica. 2015; 233:89-95.
  37. Peden MC, Suñer IJ, Hammer ME, Grizzard WS. Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti-Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration. Ophthalmology. 2015; 122:803-8.
  38. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et. al, Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 26:1193-1203.
  39. Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M., et al. Topical nepafenec in eyes with noncentral diabetic macular edema. 2015;35:944-56.
  40. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15. JAMA Ophthalmol. 2015;133:1022-9.
  41. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatment Trials. Ophthalmology. 2015;122:1846-185.
  42. Bressler NM, Varma R, Mitchell P, Suñer IJ, Dolan C, Ward J, Ferreira A, Ehrlich J, Turpcu A. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving, in Patients with Diabetic Macular Edema: Report from RESTORE, RIDE, and RISE Trials. JAMA Ophthalmol. 2016;134:160-6.
  43. Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network, Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016;134:127-34.
  44. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Ophthalmology. 2016;123:609-16.
  45. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Ophthalmology. 2016;123:858-64.
  46. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Ophthalmology. 2016;123:609-16.
  47. Suñer IJ, Bressler NM, Varma R, Dolan CM, Ward J, Trupcu A, Responsiveness of the NEI-VFQ-25 to Visual Acuity Gains in Patients with Diabetic Macular Edema: Evidence from the RIDE and RISE Trials. 2017;37:1126-33.
  48. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC, Diabetic Retinopath Clinical Research Network, Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Opthalmology. 2018; 125: 1054-1063.
  49. Peden MC, Hammer ME, Suñer IJ. Dilute Povidone-Iodine Maintains Safety While Improving Patient Comfort After Intravitreal Injections. Retina. 2018 epub ahead of print.
  50. Suñer IJ, Suñer IA, Peden MC, Hammer ME, Traynom J. The REVOLUTIONARY Trial: A Pilot Study to Assess the Efficacy, Durability, and Safety of Combination Ranibizumab + Peripheral Scatter Laser for Macular Edema Secondary to Branch Retinal Vein Occlusion Associated with Peripheral Nonperfusion on Ultrawide-field Angiography. J Clin Ophthalmol. 2018; 2:  80-5.

B) Non-Refereed Journals:

  1. Suñer IJ. How to prevent and manage infection. Rev Ophthalmol 2000;7:118-124.
  2. Suñer IJ. Cataract extraction in the presence of diabetic retinopathy. Highlights of Ophthalmology 2003;31:11-14.
  3. Suñer IJ. Diagnostic optical coherence tomography, Cataract & Refractive Surgery Today 2004;4:33-38.
  4. Suñer IJ. Dynamic ultra widefield fluorescein angiography: Creating a new standard of care, Ocular Surgery News 2005 (supplement):1-15.
  5. Suñer IJ. Age-related macular degeneration: a review. Federal Practitioner 2006 (suppl);23:4-8.
  6. Experience using pegaptanib in clinical practice. Eye News 2006;13:S1.
  7. Suñer IJ, Cousins SW. The biology of smoking and age-related macular degeneration, Rev Ophthalmol 2006 13:87-90.
  8. Suñer IJ. Surgeons and patients benefit from 25-gauge vitrectomy surgery, Retina Times 2006 24:42.
  9. Spirin MJ, Regillo CD, Kaiser RS, Olsen TW, Freund KB, Gottlieb JL, Suñer IJ. Diagnosis and management of retinal vein occlusions. Retina Times 2009;28:
  10. Suñer IJ. Taking a broader view of diabetic macular edema, Retinal Physician 2009:9-11.
  11. Suñer IJ. Vision-related function in patients with age-related macular degeneration, AMD Update 2009;30:1-2.

C) Books/Monographs/Chapters in Books:

  1. “Measuring Quality of Life for Patients with Age-Related Macular Degeneration,” Medicare Coverage Advisory Committee Technology Assessment and Presentation
  2. “Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,” in Curbside Consultation in Retina: 49 Clinical Questions (Fekrat S, editor)
  3. “Vitreous Substitutes-Gas, Fluid Viscoelastic, Silicone, Perfluorocarbon”, Tasman, W.S. and Jaeger, E.A, eds, Duane’s Clinical Ophthalmology. Philadelphia, PA: J.B. Lippincott Co; 2010.

D) Thesis Work:

  1. Suñer IJ. Studies in the purification of and the precocious induction of synthesis of juvenile hormone esterase in the tobacco hornworm, Manduca sexta. Honors thesis for Bachelor of Arts Degree, Department of Biology, Harvard University, Cambridge, MA, 1988.
  2. Suñer IJ. Influences of the lateral geniculate nucleus in the specification of primary visual cortex in Macaca mulatta. Doctoral thesis, Yale University School of Medicine, New Haven, CT, 1992.

Professional Awards and Special Recognitions:

  1. National Merit Scholar – 1984
  2. Presidential Scholar – 1984
  3. Harvard College Scholarship – 1985-1988
  4. Bachelor of Arts, Magna cum laude, Harvard University – 1988
  5. US Air Force Health Professions Scholarship, Yale School of Medicine – 1988-1992
  6. Distinguished Graduate, US Air Force Officer Training School – 1996
  7. Instructor of the Year, U.S. Air Force Physicians Assistant Training Program,
    Scott Air Force Base Medical Center, Scott AFB, IL – 1999
  8. Meritorious Service Medal, United States Air Force – 2000
  9. Honorable Discharge, United States Air Force – 2000
  10. Physician Nominee, Federal Employee of the Year, Miami VAMC – 2000
  11. Professor of the Year, Bascom Palmer Eye Institute, University of Miami
    School of Medicine, Miami, FL – 2000-2001
  12. First-Year Resident Teaching Award, Bascom Palmer Eye Institute,
    University of Miami School of Medicine, Miami, FL – 2001-2002
  13. Physician Nominee, Federal Employee of the Year, Miami VAMC – 2004
  14. Edward L. Ross Foundation Award for Macular Degeneration and Low
    Vision Care – 2005
  15. Professor of the Year, Bascom Palmer Eye Institute, University of Miami
    School of Medicine, Miami, Fl – 2004-2005
  16. Performance Award, Durham Veterans Affairs Medical Center, Durham, NC – 2005-2006
  17. Professor of the Year, Duke Eye Center, Duke University School of Medicine – 2006-2007
  18. Professor of the Year, Duke Eye Center, Duke University School of Medicine – 2007-2008
  19. Practicing Ophthalmologists Committee, Retina Section, AAO – 2008-2010
  20. Honor Award, American Society of Retina Specialists – 2008
  21. Honor Award, American Academy of Ophthalmology – 2009
  22. Senior Honor Award, American Society of Retina Specialists – 2010

Scientific Presentations at National and International Meetings:

  1. “Thermal injury during phacoemulsification,” American Academy of Ophthalmology Annual Meeting, San Francisco, CA, 1993
  2. “Hypotony maculopathy following filtering surgery with mitomycin C: incidence and treatment,” American Academy of Ophthalmology Annual Meeting, Atlanta, GA, 1995
  3. “Recurrent opacification after YAG capsulotomy in retinitis pigmentosa patients,” American Society of Cataract and Refractive Surgery Annual Meeting, Seattle, WA, 1996
  4. “Digital Imaging for Screening of Diabetic Retinopathy in U.S. Air Force: Experience with a Pilot Program,” U. S. Air Force Epidemiology Task Force, Brooks Air Force Base, TX, 2000
  5. “Central Serous Retinopathy Following LASIK,” American Society of Cataract and Refractive Surgery Annual Meeting, San Diego, CA, 2001
  6. “Nicotine Increases Severity and Size of Choroidal Neovascularization in a Mouse Model,”Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, 2002
  7. “Verteporfin Therapy with Delayed Light Application of Occult Choroidal Neovascularization in Age-Related Macular Degeneration,” Combined Retina Society and Vitreous Society Annual Meeting, San Francisco, CA, 2002
  8. “Nicotine Increases Severity of Choroidal Neovascularization in Exudative Age-Related Macular Degeneration,” Society for Research on Nicotine and Tobacco Annual Meeting, New Orleans, LA, 2003
  9. “The Effects of Nicotine in Choroidal Neovascularization: Characterization of Nicotinic Receptors in Choroid and Reduction of Choroidal Neovascularization Size and Severity via Receptor Blockade,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, 2003
  10. “Nicotine increases size and severity of experimental choroidal neovascularization,” American Society of Retina Specialists Annual Meeting, New York, NY, 2003
  11. “Nicotine Worsens Choroidal Neovascularization,” American Academy of Ophthalmology Annual Meeting, Anaheim, CA, 2003
  12. “Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental mouse model for Dry Age-Related Macular Degeneration,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May, 2004
  13. “Nicotine worsens neovascular macular degeneration,” XIIIth International Vascular Biology Meeting, Toronto, Ontario, Canada, June, 2004
  14. “Ultra-widefield angiography in the diagnosis and management of peripheral nonperfusion in diabetic retinopathy,” American Academy of Ophthalmology Annual Meeting, New Orleans, LA, October, 2004
  15. “25-gauge vitrectomy to deepen anterior chamber before cataract surgery in highly hyperopic patients,” American Society for Cataract and Refractive Surgery Annual Meeting, Washington, D.C., April, 2005
  16. “Cigarette smoke increases severity of experimental choroidal neovascularization (CNV): role of inflammation,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2005
  17. “Ultrawide-field angiography: The association of severe peripheral retinal nonperfusion with diabetic macular edema,” 18th Congress of German Ophthalmic Surgeons, Nurenberg, Germany, June 2005
  18. “The role of smoking and inflammation in choroidal neovascularization,” Retina Society Annual Meeting, San Diego, CA, September 2005
  19. “Cigarette smoke and nicotine both increase recruitment of activated macrophages in early choroidal neovascularization,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2006
  20. “Relative systemic safety of differing therapies for neovascular AMD,” American Society of Retina Specialists Annual Meeting, Cannes, France, September 2006
  21. “Vision-related quality of life through 12 months in predominantly classic neovascular AMD: an analysis of ANCHOR: a Phase III randomized trial of ranibizumab and verteporfin PDT,” Retina Society Annual Meeting, Cape Town, South Africa, October 2006
  22. “Safety of Pegaptanib Sodium in AMD: Three-Year Results of the VISION Trial,” American Academy of Ophthalmology Annual Meeting, Las Vegas, NV, October 2006
  23. “Vision-related function after ranibizumab treatment by better- or worse-seeing eye: 24-month results from MARINA,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2007
  24. “Diabetic macular edema secondary to peripheral nonperfusion: a new etiology visualized by ultra-widefield fluorescein angiography and a novel treatment strategy,” DOG Congress, Berlin, Germany, September 2007
  25. “The relationship between the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and performance-based tests,” Retina Society Annual Meeting, Boston, MA, September 2007
  26. “Improvements in Patient-Reported National Eye Institute Visual Function Questionnaire-25 (VFQ-25) Following Treatment With Ranibizumab in Neovascular AMD Patients,” American Academy of Ophthalmology Annual Meeting, New Orleans, LA, November 2007
  27. “Severe Vitritis/Sterile Endophthalmitis Associated With Intravitreous Injection of Bevacizumab,” American Academy of Ophthalmology Annual Meeting, New Orleans, LA, November 2007
  28. “Relationship of Visual Acuity and NEI-VFQ-25 Visual Function in Exudative Age-Related Macular Degeneration,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, April 2008
  29. “Ultra-widefield angiography in the diagnosis of diabetic macular edema secondary to peripheral nonperfusion: clinical characteristics and a novel treatment strategy,” Canadian Ophthalmologic Society Annual Meeting, Whistler, BC, Canada, June 2008
  30. “Driving is associated with less vision-related dependency in neovascular AMD patients,” Retina Society Annual Meeting, Scottsdale, AZ, September 2008
  31. “Neovascular AMD Patients in ANCHOR Who Still Drive Report More Control and Less Dependence on Others Than Those Who Do Not Drive,” American Society of Retina Specialists Meeting, Maui, Hawaii, October 2008
  32. “NEI VFQ-25 Activities Pertinent to Patients with Neovascular AMD,” American Academy of Ophthalmology Annual Meeting, Atlanta, November 2008
  33. “National Eye Institute Visual Function Questionnaire-25 (VFQ) Reading Items Improved Following Ranibizumab Treatment in MARINA and ANCHOR,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2009
  34. “Estimated Cases of Legal Blindness Avoided in the United States with Ranibizumab for Neovascular Age-Related Macular Degeneration,” Combined Meeting of ASRS, Retina Society, Macula Society, New York, NY, October 2009
  35. “Evaluating the Outcome in AMD Patients Who Stopped Receiving Constant Interval Dosing and Had a Recurrence of the Neovascular Process,” Combined Meeting of ASRS, Retina Society, Macula Society, New York, NY, October 2009
  36. “NEI VFQ-25 Outcomes in PIER within Subgroups Defined by OCT Fluid Status,” Combined Meeting of ASRS, Retina Society, Macula Society, New York, NY, October 2009
  37. “Improved Contrast Sensitivity in AMD Patients after Treatment with Ranibizumab in MARINA and ANCHOR,” Combined Meeting of ASRS, Retina Society, Macula Society, New York, NY, October 2009
  38. “Vision-Related Mental Health Changes in Response to Ranibizumab Therapy in MARINA and ANCHOR,” American Academy of Ophthalmology Annual Meeting, San Francisco, CA, October 2009
  39. “Improvements in Reading Speed After 6 Months of Ranibizumab Treatment in BRAVO and CRUISE,” Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 2010
  40. “RaScaL: A Pilot Study Assessing Efficacy of Ranibizumab + Peripheral Scatter Laser in DME Associated with Peripheral Nonperfusion,” American Society of Retina Specialists Annual Meeting, Vancouver, B.C., Canada, August 2010
  41. “RaScaL: A Prospective Clinical Trial Assessing Efficacy and Durability of Ultra-Widefield Angiography-Directed Scatter Laser Plus Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Peripheral Nonperfusion,” Club Jules Gonin Meeting, Kyoto, Japan, November 2010
  42. Effects of Ranibizumab on Reading Speed Through 24 Months in Patients with Vision Impairment from Diabetic Macular Edema (DME), Retina Society Annual Meeting, Rome, Italy, September 2011
  43. “Efficacy and Safety of 2.0 mg and 0.5 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration: The HARBOR Study,” World Ophthalmology Congress, Abu Dhabi, United Arab Emirates, February 2012
  44. “RaScaL Study: A novel treatment strategy for diabetic macular edema associates with peripheral retinal nonperfusion on ultrawide-field angiography,” World Ophthalmology Congress, Abu Dhabi, United Arab Emirates, February 2012
  45. “Efficacy and Safety of 2.0 mg and 0.5 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration: The HARBOR Study,” Association for Research in Vision and Ophthalmogy, Ft. Lauderdale, FL, May 2012
  46. “The HARBOR Study: Effect of Every 4 Week versus PRN Dosing with Ranibizumab (2.0 mg vs 0.5 mg) on Patient-Reported Visual Function in Subfoveal Neovascular Age-Related Macular Degeneration,” Retina Society Annual Meeting, Washington, DC, October 2012
  47. “Improved Contrast Sensitivity in Retinal Vein Occlusion Patients after Treatment with Ranibizumab in BRAVO and CRUISE,” American Society of Retina Specialists Annual Meeting, Toronto, Ontario, Canada, August 2013
  48. “Long-term Control of Macular Edema Associated with Branch Retinal Vein Occlusion with Combination Ranibizumab and Ultra-Wide Field Angiography-Guided Peripheral Scatter Laser,” Vit Buckle Society Annual Meeting, Las Vegas, NV, March 2014
  49. “Revolutionary: Novel treatment paradigm for treatment of macular edema secondary to branch retinal vein occlusion associated with peripheral nonperfusion,” Florida Society of Ophthalmology Annual Meeting, Orlando, FL June 2014
  50. REVOLUTIONARY: A Pilot Trial of Combination Peripheral Scatter Laser and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion,” American Society of Retina Specialists Annual Meeting, San Diego, CA, August 2014
  51. REVOLUTIONARY: A Pilot Trial of Combination Peripheral Scatter Laser and Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion,” Retina Society Annual Meeting, Philadelphia, PA, September 2014
  52. Long-term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti-vascular Endothelial Growth Factor Agents in Wet Age-Related Macular Degeneration (FIDO Study), Retina Society Annual Meeting, Paris, France, October 2015
  53. Long-Term Continuous Treatment of Wet AMD with Anti-vascular Endothelial Growth Factor Agents (FIDO Study): 10-Year Results, Club Vit Meeting, Mykonos, Greece, June 2017
  54. 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration (FIDO Study), Retina Society Annual Meeting, Boston, MA, October 2017

 

Invited Lectureships/Symposia and Course Participation:

  1. “Phacoemulsification course for residents in Ophthalmology,” Instructional Course, American Society of Cataract and Refractive Surgery Annual Meeting, Seattle, WA, 1996
  2. “Breakfast with the Masters: Visudyne Therapy,” Breakfast Course, Vitreous Society Annual Meeting, Las Croabas, PR, 2001
  3. “Diabetic retinopathy and cataract surgery,” 24th Annual Interamerican Course, Miami, FL 2002
  4. “Clinical trials in Age-Related Macular Degeneration,” Bascom Palmer Vitreoretinal Course, Miami, FL, 2003
  5. “Uveitis and endophthalmitis,” Joint Commission on Allied Health Personnel in Ophthalmology Northeast Regional Educational Program, New York, NY, 2003
  6. “Pharmacotherapy in Age-related Macular Degeneration,” Joint Commission on Allied Health Personnel in Ophthalmology Annual Subspecialty Symposium (Retina) Anaheim, CA, 2003
  7. “Cystoid Macular Edema,” 25th Annual Interamerican Course, Miami, FL 2003
  8. “Diabetic Macular Edema and Cystoid Macular Edema after Cataract Surgery,” American Osteopathic College of Ophthalmology Annual Meeting, Miami, FL 2004
  9. “Optical coherence tomography in preoperative and postoperative management of cataract surgery patients,” Carl Zeiss OCT Symposium, American Society of Cataract and Refractive Surgery Annual Meeting, San Diego, CA, April, 2004
  10. “Ultra-widefield angiography in the management of peripheral retinal vascular diseases,” Ultra-widefield retinal imaging CME Symposium, Annual Meeting of American Academy of Ophthalmology, New Orleans, LA, October, 2004
  11. “A practical approach to ocular trauma,” Joint Commission on Allied Health Personnel in Ophthalmology Annual Meeting, New Orleans, LA, October, 2004
  12. “25-gauge vitrectomy in the management of uveitis,” Uveitis for the Other Subspecialist Meeting at Bascom Palmer Eye Institute, Miami, FL, February, 2005
  13. “Clearing the smoke on macular degeneration: nicotine in wet macular degeneration,” 33rd Annual Aspen Retinal Detachment Society Meeting, Aspen, CO, March 2005
  14. “Ultrawide-field angiography: The association of severe peripheral retinal nonperfusion with diabetic macular edema,” 33rd Annual Aspen Retinal Detachment Society Meeting, Aspen, CO, March 2005
  15. “Cigarette smoking and wet age-related macular degeneration,” ARVO Minisymposium on smoking and age-related macular degeneration, Ft. Lauderdale, FL, May, 2005
  16. “25-gauge vitrectomy in phacoemulsification surgery: management of shallow anterior chamber and vitreous loss” Invited speaker at Puerto Rico Society of Ophthalmology Annual Meeting, Rio Grande, PR, May 2005
  17. “Transitioning to 25-gauge vitrectomy for the retina surgeon” Invited speaker at Puerto Rico Society of Ophthalmology Annual Meeting, Rio Grande, PR, May 2005
  18. “The electronic medical record in the Veterans Affairs Medical System,” Special Symposium on VA Eye Care, American Academy of Ophthalmology Annual Meeting, Chicago, IL, October 2005
  19. “A practical approach to ocular trauma,” Joint Commission on Allied Health Personnel in Ophthalmology Annual Meeting, Chicago, IL, October, 2005
  20. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, Chicago, IL, October 2005
  21. “Ultra-widefield angiography in diagnosis and management of diabetic macular edema,” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2006
  22. “Smoking and age-related macular degeneration,” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2006
  23. “Transitioning to 25-gauge vitrectomy for the retinal surgeon” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2006
  24. “VEGF Inhibition: A new treatment paradigm for all forms of wet AMD,” Keynote address, Nordic Ophthalmic Congress, Copenhagen, Denmark, June 2006
  25. “The electronic medical record in the Veterans Affairs Medical System,” Special Symposium on VA Eye Care, American Academy of Ophthalmology Annual Meeting, Las Vegas, NV, November 2006
  26. “A practical approach to ocular trauma,” Joint Commission on Allied Health Personnel in Ophthalmology Annual Meeting, Las Vegas, NV, November, 2006
  27. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, Las Vegas, NV, November 2006
  28. “The critical role of the Veterans Affairs Medical Center in resident training,” Association of University Professors of Ophthalmology Annual Meeting, Indian Wells, CA, February 2007
  29. “Smoking and age-related macular degeneration,” Raymond C. Cook Visiting Professor, Jones Eye Institute, University of Arkansas, March 2007
  30. “Pegaptanib in management of neovascular age-related macular degeneration,” Valencia Society of Ophthalmology Annual Meeting, Valencia, Spain, March 2007
  31. “Nicotine in age-related macular degeneration,” Visiting Professor Lecture commemorating retirement of Caleb Gonzalez, Yale Eye Center, New Haven, CT, May 2007
  32. “Diabetic retinopathy: a new look at an old foe. New diagnostic and therapeutic approaches,” Combined Annual Meeting of the North Carolina Society of Eye Physicians and Surgeons and the South Carolina Society of Ophthalmology, Asheville, NC, September 2007
  33. “Optical coherence tomography for the anterior segment surgeon: why you can’t afford to be without it. A case-oriented approach,” Combined Annual Meeting of the North Carolina Society of Eye Physicians and Surgeons and the South Carolina Society of Ophthalmology, Asheville, NC, September 2007
  34. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, New Orleans, LA, November 2007
  35. “A practical approach to ocular trauma,” Joint Commission on Allied Health Personnel in Ophthalmology Annual Meeting, New Orleans, LA, November, 2007
  36. “Selective Anti-VEGF Therapy Pegaptanib for all stages of Neovascular AMD,” Invited Speaker, Spanish Vitreoretinal Society Annual Meeting, Zaragoza, Spain, March 2008″
  37. Selective Anti-VEGF Therapy Pegaptanib for all stages of Neovascular AMD,” Invited Speaker, Japanese Ophthalmological Society Annual Meeting, Yokohama, Japan, April 2008
  38. “Ultra-widefield angiography in diagnosis and management of diabetic macular edema,” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2008
  39. “Smoking and age-related macular degeneration,” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2008
  40. “Advances in 25-gauge vitrectomy for the retinal surgeon” Duke Advanced Vitreoretinal Surgery Course, Durham, NC, April 2008
  41. “Ultra-widefield angiography in the evaluation and treatment of diabetic macular edema,” Retinal Physician Symposium, Naples, FL, May 2008
  42. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, Atlanta, GA, October 2008
  43. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, San Francisco, CA, October 2009
  44. “Ultra-widefield angiography,” Ophthalmic Photographers Symposium, Chicago, IL, October 2010
  45. “Vitrectomy for the anterior segment surgeon,” course and wet lab at American Academy of Ophthalmology Annual Meeting, Chicago, IL, October 2010

Organizations and Participation:

  1. American Academy of Ophthalmology, Fellow – 1993 – present
  2. American Academy of Ophthalmology, Practicing Ophthalmologists Curriculum for Maintenance of Certification (MOC) Exam Study Guide – 2008-present
  3. American Board of Ophthalmology, Oral Board Examiner – 2007 – present
  4. The Retina Society, Member – 2006 – present
  5. American Society of Retina Specialists, Member – 2002 – present
  6. American Society of Cataract and Refractive Surgery, Member – 2004 – present
  7. Association for Research in Vision and Ophthalmology, Member – 2001 – present
  8. Association of Veterans Affairs Ophthalmologists, Member – 2001 – present
    Secretary-Treasurer – 2002 – 2004
    Vice-President – 2004 – 2006
    President 2006 – 2008
  9. Club Vit – 2012- present
  10. Vit Buckle Society – 2012 – present

Editorial Experience:

A) Editorial Board:

  1. Federal Practitioner – 2004-present
  2. Ophthalmology Practice Options – 2006-present

B) Scientific Reviewer:

  1. American Journal of Ophthalmology
  2. British Journal of Ophthalmology
  3. Diabetes Care, American Diabetes Association Journal
  4. European Journal of Ophthalmology
  5. Federal Practitioner
  6. Investigative Ophthalmology and Visual Science
  7. Ophthalmic Surgery and Lasers
  8. Ophthalmology
  9. Retina
  10. Veterans Affairs Ophthalmology Association Newsletter

Teaching Responsibilities Including Continuing Education:

Duke Eye Center-Duke University School of Medicine (2005-2008):

  1. Retina Fellows:
    • Two days/wk clinic
    • 1.5 days/wk surgery
  2. Ophthalmology Residents:
    • First-year resident rotations – 20 weeks
      Introduction to OR, laser surgery, clinic supervision
    • Second-year resident rotations – 10 weeks
      Cataract Surgery (OR cases 1 day/wk)
    • Third-year residents – 10 wks
      Advanced Surgical Cases including Vitreoretinal (OR 1 day/wk)
  3. Medical students:
    • Second Year and Fourth Year Medical Student Rotation
      Clinical exam/diagnosis, surgical assisting

Bascom Palmer Eye Institute-University of Miami School of Medicine (2000-2005):

  1. Retina Fellows:
    • One day/wk clinic
    • One day/wk surgery
  2. Ophthalmology Residents:
    • First-year resident rotations – 12 weeks
      Introduction to OR, laser surgery, clinic supervision
    • Second-year residents – 6 weeks
      Cataract Surgery (OR cases 4 days/wk)
    • Third-year residents – 6 wks
      Advanced Surgical Cases including Vitreoretinal (OR 3 days/wk)
  3. Medical students:
    • Third Year and Fourth Year Medical Student Rotation
      Clinical exam/diagnosis, surgical assisting, surgery on bank eyes
    • Medical student lecture series (monthly)
      Age-related macular degeneration

Areas of Research Interest:

  1. Age-related macular degeneration: cigarette smoking, hypertension, inflammation
  2. Optical coherence tomography in evaluation of pre- and post-op cataract patients
  3. Ultra-widefield angiography scanning laser ophthalmoscopy in retinal vascular disease
  4. Digital imaging techniques and technologies for diabetic retinopathy screening
  5. Ophthalmic surgical teaching techniques

Funded Clinical Trials and Research:

  1. Cigarette Smoking in Neovascular Age-Related Macular Degeneration – 10/02-9/05
    Veterans Affairs Medical Research Merit Review Grant
    Principal Investigator: Ivan J. Suñer, M.D.
    Percent Effort: 20%
    Total Costs: $515,000
  2. Cigarette Smoking and Macrophage Activation in Neovascular Age-Related Macular Degeneration – 07/04-06/07
    Flight Attendants Medical Research Institute Grant
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Scott W. Cousins, M.D.
    Percent Effort: 10%
    Total Costs: $430,000
  3. ANCHOR Trial: Lucentis (Anti-VEGF) in Predominantly Classic Choroidal Neovascularization Secondary to Age-related Macular Degeneration – 07/03-6/05
    Genentech, South San Francisco, CA, United States
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Scott W. Cousins, M.D.
  4. MARINA Trial: Lucentis (Anti-VEGF) in Minimally Classic Choroidal Neovascularization Secondary to Age-related Macular Degeneration – 07/03-6/05
    Genentech, South San Francisco, CA, United States
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Scott W. Cousins, M.D
  5. Nicotinic Receptors in Neovascular Age-Related Macular Degeneration – 07/06-6/08
    International Retinal Research Foundation Grant
    Principal Investigator: Ivan J. Suñer, M.D.
    Percent Effort: 20%
    Total Costs: $100,000
  6. Fluocinolone Acetonide Intravitreal Insert in Diabetic Macular Edema – 11/05-present
    Alimera Sciences, Alpharetta, Georgia, United States
    Co-Investigator, Injecting Physician
  7. Posurdex in Retinal Vein Occlusion – 11/05-present
    Allergan, Irvine, CA, United States
    Co-Investigator, Injecting Physician
  8. SAILOR trial for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (FVF368g) – 11/05-present
    Genentech, South San Francisco, CA, United States
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Sharon Fekrat, M.D
  9. Anecortave Acetate Risk Reduction Trial – 11/05-present
    Alcon Labs, Dallas, TX, United States
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Sharon Fekrat, M.D
  10. Age-Related Eye Disease Study II – 11/05-12/08
    National Eye Institute, Bethesda, MD, United States
    Co-Investigator: Ivan J. Suñer, M.D.
    Principal Investigator: Scott W. Cousins, M.D
  11. Comparison of Age-Related Macular Degeneration Treatments Trials – 02/08 – 12/09
    National Eye Institute, Bethesda, MD, United States
    Principal Investigator: Ivan J. Suñer, M.D
  12. Ranibizumab and Scatter Laser in Diabetic Macular Edema Secondary to Peripheral Ischemia (RaScaL Trial) – 02/08-09/11
    Genentech, South San Francisco, CA, United States
    Optos, plc, Scotland, United Kingdom
    Principal Investigator: Ivan J. Suñer, M.D.
  13. HARBOR Trial: High-Dose Lucentis (Anti-VEGF) in Choroidal Neovascularization Secondary to Age-related Macular Degeneration – 03/09-03/12
    Genentech, South San Francisco, CA, United States
    Principal Investigator and Steering Committee Member: Ivan J. Suñer, M.D.
  14. A PHASE 1, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING DOSAGES OF RN6G IN SUBJECTS WITH ADVANCED DRY, AGE-RELATED MACULAR DEGENERATION (AMD) INCLUDING GEOGRAPHIC ATROPHY – 07/10-05/12
    New York, NY, United States
    Principal Investigator: Ivan J. Suñer, M.D.
  15. A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION – 10/10-10/11
    Ophthotech, Princeton, NJ, United States
    Principal Investigator: Ivan J. Suñer, M.D.
  16. Retinal Vein Occlusion Treatment With Scatter Laser Guided By Ultra-Widefield Angiography In Combination With Ranibizumab Study (Revolutionary Trial) – 11/10-6/12
    Genentech, South San Francisco, CA, United States
    Principal Investigator: Ivan J. Suñer, M.D.
  17. A PHASE 2 Evaluation of Topical NSAIDs in Eyes with NonCentral Involved DME – 5/11-12/13
    DRCR.net
    Principal Investigator: Ivan J. Suñer, M.D.
  18. Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy – 2/12-present
    DRCR.net
    Principal Investigator: Ivan J. Suñer, M.D.
  19. A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema – 8/12-10/18
    DRCR.net
    Principal Investigator: Ivan J. Suñer, M.D.
  20. A PHASE 3, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION – 10/13-10/16
    Ophthotech, Princeton, NJ, United States
    Principal Investigator: Ivan J. Suñer, M.D.
  21. Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity – 11/13-present
    DRCR.net
    Principal Investigator: Ivan J. Suñer, M.D.
  22. A PHASE 3  Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (GX29176):CHROMA Study – 9/14-6/17
    Genentech
    Principal Investigator: Ivan J. Suñer, M.D.
  23. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration: SEQUOIA Study – 10/15-6/18
    Allergan, Irvine, CA, United States
    Principal Investigator: Ivan J. Suñer, M.D.
  24. Intravitreous Anti-VEGF vs Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy – 11/16-present
    DRCR.net
    Principal Investigator: Ivan J. Suñer, M.D.
  25. A PHASE 2 Multicenter Randomized Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration (GX28228): LADDER Study – 3/17-3/19
    Genentech
    Principal Investigator: Ivan J. Suñer, M.D.
  26. YOSEMITE: GR40349: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA – 8/18-present
    Genentech
    Principal Investigator: Ivan J. Suñer, M.D.
  27. ARCHWAY:  GR40548: A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION – 9/18-present
    Genentech
    Principal Investigator: Ivan J. Suñer, M.D.
  28. PORTAL: GR40549: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION – 9/18-present
    Genentech
    Principal Investigator: Ivan J. Suñer, M.D.